查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1714883

自體免疫疾病診斷市場（按產品類型、測試和最終用戶分類）—2025 年至 2030 年全球預測

Autoimmune Disease Diagnostics Market by Product, Type, Test, End Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

自體免疫疾病診斷市場預計到 2024 年將達到 58 億美元，2025 年將達到 62.2 億美元，2030 年將達到 89 億美元，複合年成長率為 7.38%。

主要市場統計數據
基準年2024年 58億美元
預計年份：2025年 62.2億美元
預測年份 2030 89億美元
複合年成長率（%） 7.38%

近年來，自體免疫疾病診斷領域經歷了顯著的變革，其特點是技術進步迅速、臨床理解加深、市場動態不斷變化。隨著複雜疾病不斷挑戰傳統的診斷方法，相關人員越來越認知到創新、強大和準確的診斷工具的必要性。這項活動探索了不斷發展的診斷方法的前景，強調了重新定義自體免疫疾病檢測和管理方式的突破性發展和新興趨勢。

現代診斷環境的特徵是各學科領域的融合，從分子生物學和免疫學到生物資訊學和精準醫學。這種跨領域的合作正在促進檢測方法的發展，不僅可以提高診斷的準確性，還可以更深入地了解疾病的發病機制。這種轉變是由創新技術、不斷發展的法律規範和不斷增加的臨床數據的整合所推動的，這些數據使醫療保健提供者能夠採取更積極主動的方式來患者照護。因此，市場上的現有企業和新興企業都在大力投資研發，以便在不斷變化的市場需求中更好地競爭。

本執行摘要全面概述了當前的市場狀況，強調了塑造這一領域的變革性變化，並分析了關鍵的細分趨勢，為策略決策提供資訊。該報告採用深入分析和通俗易懂的敘述相結合的平衡方法，滿足了專業人士和決策者的資訊需求，並為自體免疫疾病診斷的未來發展和創新制定了清晰的藍圖。

一場變革將重新定義自體免疫疾病診斷領域

在過去的十年中，自體免疫疾病診斷領域發生了變革性的變化，從根本上重塑了其營運和技術模式。科學研究的不斷進步導致了更準確的生物標記和複雜的診斷演算法的開發，顯著提高了自體免疫疾病的早期檢測。同時，人工智慧和機器學習的融合為臨床醫生提供了數據主導的視角，以預測疾病進展並制定個人化治療計劃。

一個顯著的變化是從傳統的診斷方法轉向結合血清學測試和分子方法的綜合平台。人們越來越重視照護現場診斷，這有助於在臨床即時診斷中快速做出決策，從而加速這種變化。監管機構也在更新其標準以跟上這些技術進步，確保在培育競爭創新文化的同時保持品質和精確度不受影響。這些因素共同推動了模式轉移，其中診斷不再僅僅作為確認工具，而且是患者護理整體管理和策略規劃的關鍵組成部分。

技術進步也鼓勵市場參與企業投資數位轉型，從而實現實驗室工作流程的數位化和雲端基礎的數據管理系統的採用。這種數位化轉變促進了科學家之間的合作，並實現了支持臨床決策的關鍵數據的無縫交換。這些技術進步正在推動診斷實驗室和醫療保健組織從被動護理模式轉向主動護理模式，其中早期發現和及時干預構成了患者管理策略的支柱。最終，持續的顛覆性創新和策略合作為更互聯、高效和準確的診斷生態系統奠定了基礎。

揭示自體免疫疾病診斷中的關鍵細分洞察

對自體免疫疾病診斷市場的全面分析揭示了豐富的細分洞察，為了解消費行為、產品創新和技術採用提供了一個視窗。細分的關鍵維度之一是按產品，透過消耗品、檢測試劑套件和儀器等角度對市場進行複雜的審視。這些類別不僅反映了診斷測試的技術能力，而且代表了檢測開發基礎材料和方法的演變。精密儀器需求的不斷成長與耗材需求的激增相輔相成，共同推動創新和市場擴張。

另一個重要的分割參數與診斷的自體免疫疾病的類型有關。這個市場的差異在於針對局部自體免疫疾病而非局部自體免疫疾病的診斷方法。這種分類強調了局部疾病與影響多個器官或全身的疾病相比所面臨的獨特的病理和診斷挑戰。了解這些差異對於尋求根據特定臨床需求自訂診斷解決方案的相關人員來說至關重要，可擴展性和準確性至關重要。

按檢查參數細分同樣重要。診斷市場調查包括針對自身抗體和免疫反應、發炎標記和常規檢測參數的測試。這些差異化方法針對疾病進展和臨床表現的各個階段，並為醫療保健提供者提供對患者病情的細緻了解。將這些診斷測試整合到綜合疾病管理方案中，可以提高我們監測疾病進展、預測治療結果和最佳化治療方法的能力。

最後，按最終用戶進行細分可以為不同臨床環境中的不同需求提供有價值的見解。市場的最終用戶包括門診醫療中心、診斷實驗室、醫院診所、研究機構等。這些多樣化的應用強調了自體免疫疾病診斷在醫療生態系統中的廣泛實用性和關鍵重要性。透過繪製此類細分洞察，工業公司可以調整其策略，以滿足不同客戶群的特定需求，確保診斷技術的創新有效地轉化為改善患者照護和業務效率。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 自體免疫疾病盛行率不斷上升，早期診斷意識不斷增強
      • 政府努力改善疾病控制和不斷上漲的醫療成本
      • 全球專業診斷實驗室的可用性不斷提高
    • 限制因素
      • 症狀與其他疾病重疊導致假陽性的風險
    • 機會
      • 整合多種自體免疫疾病標記的綜合診斷工具的開發
      • 生物感測器在自體免疫疾病診斷上的應用
    • 任務
      • 疾病變異的複雜性影響診斷的準確性和結果
  • 市場區隔分析
    • 產品：檢測試劑套件因其能夠快速提供結果而變得越來越重要
    • 最終使用者：擴大門診護理中心對自體免疫疾病診斷的採用，以實現早期療育策略
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章自體免疫疾病診斷市場（按產品）

  • 介紹
  • 耗材和檢測試劑套件
  • 裝置

第7章自體免疫疾病診斷市場（按類型）

  • 介紹
  • 局部自體免疫疾病的診斷劑
  • 系統性自體免疫疾病的診斷劑

第 8 章自體免疫疾病診斷市場（按測試）

  • 介紹
  • 自體抗體和免疫學檢測
  • 發炎標記物
  • 定期進行實驗室檢查

第9章自體免疫疾病診斷市場（按最終用戶）

  • 介紹
  • 門診治療中心
  • 診斷實驗室
  • 醫院和診所
  • 研究所

第 10 章美洲自體免疫疾病診斷市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

11. 亞太地區自體自體免疫疾病診斷市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

12. 歐洲、中東和非洲的自體免疫疾病診斷市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abbott Laboratories
  • Abcam plc
  • AESKU.GROUP GmbH & Co. KG
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs
  • Biogenuix Medsystems Private Limited
  • bioMerieux SA
  • Danaher Corporation
  • DSS Imagetech Pvt. Ltd.
  • Exagen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Grifols, SA
  • Hemagen Diagnostics, Inc.
  • Labcorp Holdings Inc.
  • Medical & Biological Laboratories Co. Ltd
  • Menarini Group
  • Merck KGaA
  • Progentec Diagnostics, Inc.
  • Quest Diagnostics
  • Revvity, Inc.
  • RSR Limited
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity BIoTech PLC
  • Werfen Group
Product Code: MRR-436901065F36

The Autoimmune Disease Diagnostics Market was valued at USD 5.80 billion in 2024 and is projected to grow to USD 6.22 billion in 2025, with a CAGR of 7.38%, reaching USD 8.90 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 5.80 billion
Estimated Year [2025] USD 6.22 billion
Forecast Year [2030] USD 8.90 billion
CAGR (%) 7.38%

In recent years, the field of autoimmune disease diagnostics has undergone a remarkable evolution characterized by rapid technological advances, enhanced clinical understanding, and shifting market dynamics. As complex disorders continue to challenge traditional diagnostic approaches, stakeholders have increasingly recognized the need for innovative, robust, and precise diagnostic tools. This introductory section sets the stage by exploring the evolving landscape of diagnostic methodologies, highlighting groundbreaking developments and emerging trends that are redefining how autoimmune disorders are detected and managed.

The modern diagnostics environment is marked by a confluence of disciplines, ranging from molecular biology and immunology to bioinformatics and precision medicine. Such cross-disciplinary collaboration has spurred the development of assays that not only improve diagnostic accuracy but also provide deeper insights into disease pathogenesis. This transformation is driven by the convergence of innovative technologies, evolving regulatory frameworks, and a growing body of clinical data that collectively empower healthcare providers to adopt a more proactive approach to patient care. As a result, both established and emerging players in the market are investing significantly in research and development to fortify their competitive positioning amidst ever-changing market demands.

This executive summary provides a comprehensive overview of the current market scenario, articulates the transformative shifts that are shaping the field, and dissects key segmentation trends that inform strategic decision-making. By adopting a balanced approach that combines detailed analysis with an accessible narrative, this report aligns with the information needs of experts and decision-makers alike, establishing a clear roadmap for future growth and innovation in autoimmune disease diagnostics.

Transformative Shifts Redefining the Autoimmune Disease Diagnostics Arena

Over the past decade, the autoimmune disease diagnostics sector has witnessed transformative shifts that are radically reconfiguring its operational and technological paradigms. Ongoing advancements in scientific research have led to more accurate biomarkers and refined diagnostic algorithms that significantly enhance the early identification of autoimmune disorders. Simultaneously, the integration of artificial intelligence and machine learning is providing a data-driven lens through which clinicians can predict disease progression and tailor personalized treatment plans.

A notable shift in the landscape is the transition from conventional diagnostic methodologies to integrated platforms that combine serological testing with molecular approaches. This change is further accelerated by an increased emphasis on point-of-care diagnostics, which facilitate rapid decision-making in clinical settings. Regulatory bodies are also revising standards to accommodate these innovations, ensuring that quality and accuracy remain uncompromised while fostering a climate of competitive innovation. Combined, these factors are driving a paradigm shift where diagnostics are not merely tools for confirmation but serve as critical components in the overall management and strategic planning of patient treatments.

Technological advancements have also propelled market players to invest in digital transformation, leading to the digitization of laboratory workflows and the adoption of cloud-based data management systems. This digital shift is fostering collaboration among scientists and enabling the seamless exchange of critical data that supports clinical decision-making. The evolution of these technologies is empowering diagnostic laboratories and healthcare institutions to transition from reactive to proactive care models, wherein early detection and timely intervention form the backbone of patient management strategies. Ultimately, the disruptive innovations and strategic collaborations currently underway are setting the stage for a more interconnected, efficient, and accurate diagnostics ecosystem.

Unveiling Key Segmentation Insights in Autoimmune Disease Diagnostics

A comprehensive analysis of the autoimmune disease diagnostics market reveals a rich tapestry of segmentation insights that offer a window into consumer behavior, product innovation, and technological adoption. One of the primary dimensions of segmentation is based on product, where the market is intricately studied through the lens of consumables and assay kits as well as instruments. These categories not only reflect the technical capabilities of diagnostic tests but also indicate an evolution in the materials and methodologies that underpin assay development. The growing demand for high-precision instruments complements the surge in consumables, collectively driving innovation and market expansion.

Another critical segmentation parameter revolves around the type of autoimmune condition being diagnosed. The market is differentiated by the deployment of localized autoimmune disease diagnostics as opposed to diagnostics geared towards systemic autoimmune diseases. This division underscores the distinct pathology and diagnostic challenges associated with localized disorders compared to those affecting multiple organs or systems. Understanding these differences is vital for stakeholders aiming to tailor diagnostic solutions to specific clinical needs while ensuring that scalability and accuracy remain at the forefront.

Equally important is the segmentation based on test parameters. The diagnostic market is studied in terms of tests that target autoantibodies and immunologic responses, inflammatory markers, and routine laboratory tests. These differentiated approaches cater to various stages of disease progression and clinical presentations, offering healthcare providers a nuanced understanding of a patient's condition. The integration of these diagnostic tests into comprehensive disease management protocols has enhanced the ability to monitor disease evolution, predict therapeutic outcomes, and optimize treatment modalities.

Finally, segmentation based on end users offers valuable insights into the varied demand across different clinical settings. The market's end user profile includes ambulatory care centers, diagnostic laboratories, hospitals and clinics, and research institutions. This diversity in application underscores the broad utility and critical importance of autoimmune disease diagnostics across healthcare ecosystems. By mapping these segmentation insights, industry players can fine-tune their strategies to meet the specific needs of diverse customer segments, ensuring that innovations in diagnostic technology translate effectively into patient care improvements and operational efficiencies.

Based on Product, market is studied across Consumables & Assay Kits and Instruments.

Based on Type, market is studied across Localized Autoimmune Disease Diagnostics and Systemic Autoimmune Disease Diagnostics.

Based on Test, market is studied across Autoantibodies & Immunologic Test, Inflammatory Markers, and Routine Laboratory Tests.

Based on End Users, market is studied across Ambulatory Care Centers, Diagnostic Laboratories, Hospitals & Clinics, and Research Institutions.

Key Regional Insights Driving Growth and Innovation

A granular examination of the autoimmune disease diagnostics market on a regional level provides a nuanced understanding of growth patterns and innovation drivers. In the Americas, market dynamics are bolstered by a strong healthcare infrastructure, progressive adoption of advanced diagnostic technologies, and a heightened focus on precision medicine. Research and clinical institutions in this region are actively integrating new diagnostic modalities, which is further propelling the need for advanced tools that ensure early and accurate disease detection.

The Europe, Middle East & Africa region is witnessing a steady expansion fueled by collaborative efforts among academic institutions, government bodies, and industry partners. In these areas, harmonization of regulatory frameworks and an increasing emphasis on patient-centric care have accelerated the adoption of innovative diagnostic solutions. This region is also marked by significant investments in research and development, positioning it as a hotbed for pioneering advancements in autoimmune disease diagnostics.

In the Asia-Pacific region, rapid economic growth coupled with an expanding middle class is driving demand for state-of-the-art healthcare services, including cutting-edge diagnostic technologies. The integration of advanced diagnostics into both urban and emerging healthcare ecosystems is not only enhancing disease management but is also creating new avenues for market expansion. These regional insights collectively underline the importance of tailored diagnostic solutions that meet the unique healthcare needs of diverse populations and clinical environments, ensuring that the benefits of technological innovation are realized on a global scale.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Pioneering Innovation in the Autoimmune Diagnostics Market

Leading the charge in the realm of autoimmune disease diagnostics are key industry players that consistently push the boundaries of innovation and quality. Prominent names, including Abbott Laboratories, Abcam plc, AESKU.GROUP GmbH & Co. KG, Bio-Rad Laboratories, Inc., and BioAgilytix Labs, have established themselves as vanguards in developing advanced diagnostic solutions that address both existing and emerging challenges. These organizations have leveraged their deep expertise in immunology and molecular diagnostics to develop assays with enhanced sensitivity and specificity.

Companies such as Biogenuix Medsystems Private Limited and bioMerieux SA have complemented this innovation with robust portfolios that integrate cutting-edge laboratory technologies. Giants like Danaher Corporation and F. Hoffmann-La Roche Ltd. are instrumental in driving large-scale market transformation through strategic investments in research and development and robust global distribution networks. Alongside these, organizations including DSS Imagetech Pvt. Ltd., Exagen Inc., and Grifols, S.A are recognized for their commitment to delivering high-quality diagnostics that cater to a diverse range of clinical settings.

Other influential players such as Hemagen Diagnostics, Inc., Labcorp Holdings Inc., and Medical & Biological Laboratories Co. Ltd have made significant strides in refining their diagnostic assays while ensuring their solutions consistently deliver high performance in clinical settings. The Menarini Group, Merck KGaA, and Progentec Diagnostics, Inc. further exemplify the focus on innovation and operational excellence through their continuous efforts to expand and diversify their diagnostic toolsets. Companies like Quest Diagnostics, Revvity, Inc., and RSR Limited also play a crucial role by offering specialized diagnostic solutions that enhance early detection and precise disease monitoring. Cutting-edge technologies produced by Siemens Healthineers AG, Thermo Fisher Scientific Inc., Trinity Biotech PLC, and Werfen Group are setting new benchmarks in the diagnostics market, underscoring the importance of strategic investments, collaborative innovation, and unwavering commitment to quality across the industry.

The report delves into recent significant developments in the Autoimmune Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abcam plc, AESKU.GROUP GmbH & Co. KG, Bio-Rad Laboratories, Inc., BioAgilytix Labs, Biogenuix Medsystems Private Limited, bioMerieux SA, Danaher Corporation, DSS Imagetech Pvt. Ltd., Exagen Inc., F. Hoffmann-La Roche Ltd., Grifols, S.A, Hemagen Diagnostics, Inc., Labcorp Holdings Inc., Medical & Biological Laboratories Co. Ltd, Menarini Group, Merck KGaA, Progentec Diagnostics, Inc., Quest Diagnostics, Revvity, Inc., RSR Limited, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Trinity Biotech PLC, and Werfen Group. Actionable Recommendations for Industry Leaders

Industry leaders and decision-makers must be adept at navigating the multifaceted challenges presented by the rapidly evolving landscape of autoimmune disease diagnostics. To ensure sustained competitive advantage, a series of strategic actions are recommended. First, companies should elevate their investments in research and development initiatives to capitalize on breakthrough technologies that enhance assay sensitivity, specificity, and overall diagnostic accuracy. By actively collaborating with academic institutions and leveraging cross-disciplinary expertise, organizations can expedite the translation of emerging research into clinical applications.

Another critical recommendation is to embrace digital transformation. The integration of data analytics, artificial intelligence, and machine learning into diagnostic protocols can unlock the potential of large datasets, enabling more precise and predictive diagnostics. These technologies offer opportunities not only to improve the robustness of diagnostic insights but also to streamline laboratory workflows and reduce the time-to-result, thereby significantly enhancing patient outcomes.

Engaging in strategic partnerships and alliances is also essential. By forging collaborations with technology vendors, healthcare providers, and regulatory bodies, companies can collectively address market uncertainties and align on common goals for quality and innovation. This collaborative approach is particularly important in an environment where regulatory compliance and rapid technological adaptation are paramount. Moreover, leaders should consider diversifying their product portfolios to cover both consumables and high-end instruments, ensuring that there is a balanced focus on both immediate market needs and long-term strategic innovation.

Finally, it is imperative that organizations maintain a proactive stance towards emerging market trends and regional dynamics. Tailoring solutions to meet the unique demands of diverse clinical settings-whether in high-integrated healthcare environments of the Americas, the regulatory harmonization efforts in Europe, Middle East & Africa, or the dynamic growth markets in Asia-Pacific-will be key to sustaining growth and fostering long-term resilience in the competitive landscape of autoimmune diagnostics.

Conclusion: Embracing the Future of Autoimmune Diagnostics

The journey through the current landscape of autoimmune disease diagnostics underscores significant trends, transformative shifts, and robust segmentation insights that are sculpting the future of healthcare. With technological innovations pushing the boundaries of traditional diagnostics and the integration of digital tools enhancing precision, the market is set on an upward trajectory. The regional diversifications and notable performances of leading companies underscore the widespread and sustained momentum within the industry.

Ultimately, as research continues to unveil deeper insights into the immunologic underpinnings of autoimmune diseases, the evolution of diagnostic tools will play an increasingly pivotal role in personalized patient care. An optimal blend of advanced diagnostic techniques, strategic collaborations, and proactive leadership will be essential in turning these opportunities into tangible benefits for patients and healthcare providers alike. As the diagnostic landscape transforms, the challenges and opportunities that lie ahead will necessitate a commitment to quality, innovation, and collaborative growth.

This comprehensive analysis reaffirms that the future of autoimmune disease diagnostics is not only promising but is also on a clear trajectory towards more integrated, efficient, and patient-centric approaches. Embracing these developments will be critical for all stakeholders committed to making impactful contributions in the realm of healthcare.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of autoimmune diseases coupled with increasing awareness for early diagnosis
      • 5.1.1.2. Rising government initiatives and healthcare expenditure for improved disease management
      • 5.1.1.3. Increasing availability of specialized diagnostic laboratories globally
    • 5.1.2. Restraints
      • 5.1.2.1. Risk of false positives due to overlapping symptoms with other medical conditions
    • 5.1.3. Opportunities
      • 5.1.3.1. Developing comprehensive diagnostic tools integrating multiple autoimmune disease markers
      • 5.1.3.2. Adoption of biosensors for autoimmune disease diagnosis
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity of disease heterogeneity affecting diagnostic accuracy and outcomes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising significance of assay kits owing to their ability to provide rapid results
    • 5.2.2. End Users: Expanding adoption of autoimmune disease diagnostics among ambulatory care centers for early intervention strategies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Autoimmune Disease Diagnostics Market, by Product

  • 6.1. Introduction
  • 6.2. Consumables & Assay Kits
  • 6.3. Instruments

7. Autoimmune Disease Diagnostics Market, by Type

  • 7.1. Introduction
  • 7.2. Localized Autoimmune Disease Diagnostics
  • 7.3. Systemic Autoimmune Disease Diagnostics

8. Autoimmune Disease Diagnostics Market, by Test

  • 8.1. Introduction
  • 8.2. Autoantibodies & Immunologic Test
  • 8.3. Inflammatory Markers
  • 8.4. Routine Laboratory Tests

9. Autoimmune Disease Diagnostics Market, by End Users

  • 9.1. Introduction
  • 9.2. Ambulatory Care Centers
  • 9.3. Diagnostic Laboratories
  • 9.4. Hospitals & Clinics
  • 9.5. Research Institutions

10. Americas Autoimmune Disease Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Autoimmune Disease Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Autoimmune Disease Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Augurex Life Sciences Corp. partnered with ARUP Laboratories to include the 14-3-3η protein test
    • 13.3.2. AliveDx announces LumiQ, an automated immunofluorescence assay solution
    • 13.3.3. Argenx SE announced the approval of VYVGART (efgartigimod alfa) in Japan for adults
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Abcam plc
  • 3. AESKU.GROUP GmbH & Co. KG
  • 4. Bio-Rad Laboratories, Inc.
  • 5. BioAgilytix Labs
  • 6. Biogenuix Medsystems Private Limited
  • 7. bioMerieux SA
  • 8. Danaher Corporation
  • 9. DSS Imagetech Pvt. Ltd.
  • 10. Exagen Inc.
  • 11. F. Hoffmann-La Roche Ltd.
  • 12. Grifols, S.A
  • 13. Hemagen Diagnostics, Inc.
  • 14. Labcorp Holdings Inc.
  • 15. Medical & Biological Laboratories Co. Ltd
  • 16. Menarini Group
  • 17. Merck KGaA
  • 18. Progentec Diagnostics, Inc.
  • 19. Quest Diagnostics
  • 20. Revvity, Inc.
  • 21. RSR Limited
  • 22. Siemens Healthineers AG
  • 23. Thermo Fisher Scientific Inc.
  • 24. Trinity Biotech PLC
  • 25. Werfen Group

LIST OF FIGURES

  • FIGURE 1. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET MULTI-CURRENCY
  • FIGURE 2. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 4. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ASSAY KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY LOCALIZED AUTOIMMUNE DISEASE DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AUTOANTIBODIES & IMMUNOLOGIC TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY INFLAMMATORY MARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY ROUTINE LABORATORY TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 190. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 191. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024